Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an ...

"We are fighting for cures for our daughter Maggie, who we miss immensely every single day," said her parents, who founded Maggie's Mission.

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Fallopian Tube Cancer.

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Peritoneal Cancer.